Loading clinical trials...
Loading clinical trials...
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B
Conditions
Interventions
AAV5-hFIXco-Padua
Locations
28
United States
10-15 Phoenix Childrens Hospital
Phoenix, Arizona, United States
10-14 Arkansas Children's Hospital - Pharmacology
Little Rock, Arkansas, United States
10-22 Orthopaedic Institute for Children
Los Angeles, California, United States
10-21 Children's Hospital of Los Angeles
Los Angeles, California, United States
10-63 UC Davis Medical Center
Sacramento, California, United States
10-12 University of California, San Diego (UCSD)
San Diego, California, United States
Start Date
August 30, 2023
Primary Completion Date
March 23, 2035
Completion Date
March 23, 2035
Last Updated
July 18, 2025
NCT03961243
NCT06820515
NCT06379789
NCT06008938
NCT04645199
NCT07080905
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions